InnoPharmax Inc. 4172.TWO Stock
InnoPharmax Inc. Price Chart
InnoPharmax Inc. 4172.TWO Financial and Trading Overview
InnoPharmax Inc. stock price | 15.2 TWD |
Previous Close | 23.25 TWD |
Open | 23.65 TWD |
Bid | 26.5 TWD x 0 |
Ask | 26.7 TWD x 0 |
Day's Range | 23.15 - 27 TWD |
52 Week Range | 10.8 - 27 TWD |
Volume | 6.54M TWD |
Avg. Volume | 833.83K TWD |
Market Cap | 2.46B TWD |
Beta (5Y Monthly) | 0.84041 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.77 TWD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
4172.TWO Valuation Measures
Enterprise Value | 1.75B TWD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 84.33005 |
Price/Book (mrq) | 5.379811 |
Enterprise Value/Revenue | 60.145 |
Enterprise Value/EBITDA | -19.598 |
Trading Information
InnoPharmax Inc. Stock Price History
Beta (5Y Monthly) | 0.84041 |
52-Week Change | 82.86% |
S&P500 52-Week Change | 20.43% |
52 Week High | 27 TWD |
52 Week Low | 10.8 TWD |
50-Day Moving Average | 18.46 TWD |
200-Day Moving Average | 14.46 TWD |
4172.TWO Share Statistics
Avg. Volume (3 month) | 833.83K TWD |
Avg. Daily Volume (10-Days) | 1.53M TWD |
Shares Outstanding | 88.03M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -320.35% |
Gross Margin | -1.29% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -11.15% |
Return on Equity (ttm) | -21.43% |
Income Statement
Revenue (ttm) | 29.13M TWD |
Revenue Per Share (ttm) | 0.34 TWD |
Quarterly Revenue Growth (yoy) | -26.60% |
Gross Profit (ttm) | -377000 TWD |
EBITDA | -89407000 TWD |
Net Income Avi to Common (ttm) | -103181000 TWD |
Diluted EPS (ttm) | -1.23 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 104.57M TWD |
Total Cash Per Share (mrq) | 1.2 TWD |
Total Debt (mrq) | 37.56M TWD |
Total Debt/Equity (mrq) | 8.71 TWD |
Current Ratio (mrq) | 3.495 |
Book Value Per Share (mrq) | 4.963 |
Cash Flow Statement
Operating Cash Flow (ttm) | -100076000 TWD |
Levered Free Cash Flow (ttm) | -56270624 TWD |
Profile of InnoPharmax Inc.
Country | Taiwan |
State | N/A |
City | Taipei |
Address | No.22, Ruiguang Road |
ZIP | 11492 |
Phone | 886 2 8797 7607 |
Website | https://www.innopharmax.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 34 |
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin and GemOral. Its core technology is OralPAS Pro platform, a solid-SMEDDS dosage form composed of peptide drug, solvent, co-solvent, and surfactant adsorbed onto granules by inert excipients. The company offers anti-infection agents, including Bestnem, an imipenem and cilastatin sodium solution that is used intravenous in the treatment of various infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, or bone and joint infections; and various complicated or uncomplicated urinary tract infections, septicemia, or endocarditis caused by susceptible organisms. It also provides contrast agents consisting of gadopentetate dimeglumine and gadodiamide. In addition, the company offers oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. The company was founded in 2005 and is based in Taipei City, Taiwan. InnoPharmax Inc. is a subsidiary of Synmosa Biopharma Corporation.
Q&A For InnoPharmax Inc. Stock
What is a current 4172.TWO stock price?
InnoPharmax Inc. 4172.TWO stock price today per share is 15.2 TWD.
How to purchase InnoPharmax Inc. stock?
You can buy 4172.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InnoPharmax Inc.?
The stock symbol or ticker of InnoPharmax Inc. is 4172.TWO.
Which industry does the InnoPharmax Inc. company belong to?
The InnoPharmax Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does InnoPharmax Inc. have in circulation?
The max supply of InnoPharmax Inc. shares is 95M.
What is InnoPharmax Inc. Price to Earnings Ratio (PE Ratio)?
InnoPharmax Inc. PE Ratio is now.
What was InnoPharmax Inc. earnings per share over the trailing 12 months (TTM)?
InnoPharmax Inc. EPS is -0.77 TWD over the trailing 12 months.
Which sector does the InnoPharmax Inc. company belong to?
The InnoPharmax Inc. sector is Healthcare.